Giovanni Marasco1, Antonio Colecchia2, Maria Letizia Bacchi Reggiani3, Ciro Celsa4, Fabio Farinati5, Edoardo Giovanni Giannini6, Francesca Benevento7, Gian Ludovico Rapaccini8, Eugenio Caturelli9, Mariella Di Marco10, Elisabetta Biasini11, Fabio Marra12, Filomena Morisco13, Francesco Giuseppe Foschi14, Marco Zoli7, Antonio Gasbarrini15, Gianluca Svegliati Baroni16, Alberto Masotto17, Rodolfo Sacco18, Giovanni Raimondo19, Francesco Azzaroli20, Andrea Mega21, Gianpaolo Vidili22, Maurizia Rossana Brunetto23, Gerardo Nardone24, Elton Dajti20, Federico Ravaioli20, Francesca Avanzato25, Davide Festi26, Franco Trevisani27. 1. Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italia; Department of Medical and Surgical Science, Gastroenterology Unit, University of Bologna, Bologna, Italy. Electronic address: giovanni.marasco4@unibo.it. 2. Gastroenterology Unit, Borgo Trento Hospital Verona, Verona, Italy. 3. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. 4. Section of Gastroenterology and Hepatology, Department Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza (PROMISE), University of Palermo, Italy. 5. Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. 6. Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Policlinico San Martino, Genoa, Italy. 7. Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italia; Department of Medical and Surgical Sciences, Division of Internal Medicine, University of Bologna, Bologna, Italy. 8. Division of Internal Medicine and Gastroenterology, Complesso Integrato Columbus, Università Cattolica del Sacro Cuore, Rome, Italy. 9. Gastroenterology Unit, Ospedale Belcolle, Viterbo, Italy. 10. Division of Medicine, Bolognini Hospital, Seriate, Italy. 11. Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Italy. 12. Internal Medicine and Hepatology, Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy. 13. Department of Clinical Medicine and Surgery, Unit of Gastroenterology and Hepatology, University of Naples, "Federico II," Naples, Italy. 14. Department of Internal Medicine, Ospedale per gli Infermi di Faenza, Faenza, Italy. 15. Division of Internal Medicine and Gastroenterology, Policlinico Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy. 16. Liver Injury and Transplant Unit, Polytechnic University of Marche, Ancona, Italy. 17. Gastroenterology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Italy. 18. Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Italy. 19. Division of Clinical and Molecular Hepatology, University of Messina, Messina, Italy. 20. Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italia; Department of Medical and Surgical Science, Gastroenterology Unit, University of Bologna, Bologna, Italy. 21. Division of Gastroenterology, Bolzano Regional Hospital, Bolzano, Italy. 22. Department of Medical, Surgical and Experimental Sciences. U.O.C. Clinica Medica, University of Sassari, Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy. 23. Hepatology and Liver Physiopathology Laboratory and Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. 24. Department of Clinical Medicine and Surgery, Hepato-Gastroenterology Unit, University of Naples "Federico II," Naples, Italy. 25. Department of Medical and Surgical Sciences, Division of Semeiotics, University of Bologna, Bologna, Italy. 26. Department of Medical and Surgical Science, Gastroenterology Unit, University of Bologna, Bologna, Italy. 27. Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, Bologna, Italia; Department of Medical and Surgical Sciences, Division of Semeiotics, University of Bologna, Bologna, Italy.
Abstract
BACKGROUND: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. AIMS: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. METHODS: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). RESULTS: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p<0.001) at univariate analysis, except the Albumin-Bilirubin score. The Italian Liver Cancer score (CLIP) yielded the highest accuracy (C-index 0.604, AIC 9898), followed by the ITA.LI.CA. prognostic score (C-index 0.599, AIC 9915). CONCLUSIONS: The CLIP score had the highest accuracy in predicting the overall survival of HCC patients treated with Sorafenib, although its performance remained poor. Further studies are needed to refine the current ability to predict the outcome of HCC patients undergoing Sorafenib.
BACKGROUND: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. AIMS: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. METHODS: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). RESULTS: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p<0.001) at univariate analysis, except the Albumin-Bilirubin score. The Italian Liver Cancer score (CLIP) yielded the highest accuracy (C-index 0.604, AIC 9898), followed by the ITA.LI.CA. prognostic score (C-index 0.599, AIC 9915). CONCLUSIONS: The CLIP score had the highest accuracy in predicting the overall survival of HCC patients treated with Sorafenib, although its performance remained poor. Further studies are needed to refine the current ability to predict the outcome of HCC patients undergoing Sorafenib.
Authors: Muhammad O Awiwi; Khaled M Elsayes; Yehia I Mohamed; Lina Altameemi; Migena Gjoni; Omayr Muhammad Irshad; Ahmed Sayed Ahmed; Ahmad O Kaseb; Usama Salem Journal: J Hepatocell Carcinoma Date: 2022-08-30
Authors: Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li Journal: Biomed Res Int Date: 2021-07-22 Impact factor: 3.411